Literature DB >> 22513513

Cognitive impairment in multiple sclerosis.

P J Jongen1, A T Ter Horst, A M Brands.   

Abstract

Cognitive impairment occurs in 40-65% of multiple sclerosis (MS) patients, typically involving complex attention, information processing speed, (episodic) memory and executive functions. It is seen in the subclinical radiologically isolated syndrome, clinically isolated syndrome, and all phases of clinical MS. In pediatric-onset MS cognition is frequently impaired and worsens relatively rapidly. Cognitive impairment often affects personal life and vocational status. Depression, anxiety and fatigue aggravate symptoms, whereas cognitive reserve partially protects. Cognitive dysfunction correlates to brain magnetic resonance imaging (MRI) lesion volumes and (regional) atrophy, and degree of and increase in MRI abnormalities predict further worsening. Experimental MRI indicates a crucial role for (focal) cortical lesions and atrophy, abnormal cortical integrity, and early changes in normal appearing brain tissue. Functional MRI suggests compensatory reorganization and adaptation changes in neural activities. Screening tools are the Brief Repeatable Neuropsychological Battery, Symbol Digit Modalities Test and Audio Recorded Cognitive Screen. The Minimal Assessment of Cognitive Function in Multiple Sclerosis (MS) is used for formal neuropsychological evaluation. What constitutes a clinically relevant change and how to optimally monitor cognition are issues to be settled. In relapsing-remitting MS timely and adequate disease modifying drug treatment may stabilize or possibly improve cognition. There is no evidence-based symptomatic drug treatment, nor are there optimal non-pharmacological approaches. Leisure activities enhance cognitive reserve. Cognitive rehabilitation in MS patients is still in its infancy. Cognitive behavioral therapy, exercise, and education programs are promising psychosocial interventions to improve coping and lessen cognitive symptoms.

Entities:  

Mesh:

Year:  2012        PMID: 22513513

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  34 in total

1.  Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis.

Authors:  Maria Pia Amato; Benedetta Goretti; Vincenzo Brescia Morra; Paolo Gallo; Mauro Zaffaroni; Marco Onofrj; Eleonora Cocco; Giovanna Borriello; Valentina Zipoli; Maria Trojano
Journal:  Neurol Sci       Date:  2020-05-01       Impact factor: 3.307

2.  Restless legs syndrome, sleep quality, and perceived cognitive impairment in adults with multiple sclerosis.

Authors:  Katie L J Cederberg; Brenda Jeng; Jeffer E Sasaki; Robert W Motl
Journal:  Mult Scler Relat Disord       Date:  2020-05-18       Impact factor: 4.339

Review 3.  [Coexistent depressive and anxiety disorders in epilepsy and multiple sclerosis: a challenge to neuropsychiatric practice].

Authors:  Hans-Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2014-05-20

4.  Self-management for people with multiple sclerosis: report from the first international consensus conference, november 15, 2010.

Authors:  Robert Fraser; Dawn Ehde; Dagmar Amtmann; Aimee Verrall; Kurt L Johnson; Erica Johnson; George H Kraft
Journal:  Int J MS Care       Date:  2013

5.  MFPCA: Multiscale Functional Principal Component Analysis.

Authors:  Zhenhua Lin; Hongtu Zhu
Journal:  Proc Conf AAAI Artif Intell       Date:  2019 Jan-Feb

6.  Copper chelation and autoimmunity differentially impact myelin in the hippocampal-prefrontal circuit.

Authors:  Mara Nickel; Farida Eid; Peter Jukkola; Chen Gu
Journal:  J Neuroimmunol       Date:  2019-06-20       Impact factor: 3.478

7.  Self-efficacy as a predictor of self-reported physical, cognitive, and social functioning in multiple sclerosis.

Authors:  Margaret M Schmitt; Yael Goverover; John Deluca; Nancy Chiaravalloti
Journal:  Rehabil Psychol       Date:  2013-12-09

8.  Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) in the Italian population.

Authors:  Simone Migliore; Anna Ghazaryan; Ilaria Simonelli; Patrizio Pasqualetti; Doriana Landi; Maria Giuseppina Palmieri; Filomena Moffa; Pasquale Rinaldi; Fabrizio Vernieri; Maria Maddalena Filippi
Journal:  Neurol Sci       Date:  2016-04-20       Impact factor: 3.307

9.  Sleep Disturbance and Cognitive Dysfunction in Multiple Sclerosis: a Systematic Review.

Authors:  Abbey J Hughes; Katherine M Dunn; Trisha Chaffee
Journal:  Curr Neurol Neurosci Rep       Date:  2018-01-29       Impact factor: 5.081

10.  Alterations in functional connectivity are associated with white matter lesions and information processing efficiency in multiple sclerosis.

Authors:  José Miguel Soares; Raquel Conde; Ricardo Magalhães; Paulo Marques; Rosana Magalhães; Luciana Gomes; Óscar F Gonçalves; Mavilde Arantes; Adriana Sampaio
Journal:  Brain Imaging Behav       Date:  2021-02       Impact factor: 3.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.